INS-3001 is under clinical development by Vifor Pharma Management and currently in Phase I for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD). According to GlobalData, Phase I drugs for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INS-3001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INS-3001 is under development for the treatment of vascular calcification in aortic valve stenosis, peripheral arterial disease (PAD) and arterial stiffness in chronic kidney disease patients. It is administered through subcutaneous route. The drug candidate is inositol hexaphosphate (IP6) based product. The drug candidate is developed based on Inositune technology.
Vifor Pharma Management overview
Vifor Pharma Management (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines for unmet medical needs of the gastrointestinal tract. It operates production plants in Portugal and Switzerland, and carries out business through subsidiaries. Vifor Pharma is headquartered in St. Gallen, Switzerland.
For a complete picture of INS-3001’s drug-specific PTSR and LoA scores, buy the report here.